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Abstract
Introduction: At present, doxorubicin (DOX) is the most popular anthracycline antibiotic in oncology. The search 
for substances with a cardiotropic effect in DOX-associated cardiomyopathy is conducted among various classes of 
chemical and pharmacological groups. Research Tasks: Development of methodological approaches for evaluation 
of cardioprotective activity of drugs in doxorubicin cardiomyopathy. Materials and Methods: Simulation of the 
cardiomyopathy was performed by intraperitoneal administration of DOX at a dose of 20 mg/kg 1 time per day. 
After 48 h, we assessed indices of a left ventricular contractility under conditions of high heart rate 480 bmp for 15 
s on an isolated Langendorff heart of rats. As an additional index of the assessment of the cardioprotective action of 
pharmacological agents, S
tТТI
 coefficient was used, reflecting the diastole defect, which is an area under the curve of the 
buildup of an end diastolic pressure. To evaluate the myocardial damage, the isoenzyme creatine phosphokinase-MB 
and lactate dehydrogenase (LDH) in perfusate flowing from the isolated hearts were determined. For a comprehensive 
confirmation of the development of the simulated pathological processes, a morphological study of the hearts was 
performed. As drugs, enalaprilat (KRKA Slovenia) at the dose of 5 mg/kg intraperitoneally every 12 h, carvedilol 
(Teva, Israel) per os 1 time a day, and verapamil (JSC Alkaloid, Macedonia) at the dose of 5 mg/kg intraperitoneally 
1 time a day were used. Results: In a control group with the DOX-induced cardiomyopathy under the conditions of 
submaximal stimulation frequencies (480 bpm), we observed the diastolic defect which numerically was S
tТТI
 = 8.3 ± 
0.3 c.u. which shows significant damage and the failure of the calcium pumps of cardiac myocytes. In an intact group, 
S
tТТI
 coefficient was 1.4 ± 0.1 c.u. which is 8 times less than in the control group. The results of biochemical and 
morphological studies confirmed the degree of myocardial damage. In the comparative analysis of cardioprotective 
activity of drugs in doxorubicin cardiomyopathy, the studied compounds were located in the following sequence: 
Enalaprilat (5 mg/kg), carvedilol (30 mg/kg), verapamil (5 mg/kg). Conclusion: The fundamental difference in the 
area under the curve of the buildup of the end diastolic pressure under the conditions of submaximal stimulation 
frequencies (480 bpm) for 15 s in the intact group and the control group on the background of DOX administration 
naturally led to the necessity of introducing S
tТТI
 coefficient, which is quite revealing and informative. The obtained 
results allow to use S
tТТI
 at the screening of innovative molecules.
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The search for innovative molecules[1,2] with cardioprotective activity is an important task of pharmacology. In 
this case, their study should be conducted on 
pharmacological targets, which provides a 
targeted search for the creation of new drugs.[3-5] 
Today, different methods are proposed for the 
assessment of the cardioprotective activity of 
pharmacological agents: Check the absorption 
of calcium ions by isolated heart of rats,[6] the tests for the load 
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of the heart by permanent wave Doppler echocardiography 
in dogs with mitral regurgitation,[9] and others. However, 
the performance, information, and reliability of these 
methods are insufficient. The introduction of new methods 
of assessment of the cardioprotective actions is an actual 
task. Among pharmacological models of cardiomyopathy, 
features of doxorubicin (DOX)-induced cardiomyopathy 
are a progressive decline in the contractility of the left 
ventricular myocardium and the development of the diastolic 
defect.[10] It is possible to overcome the cardiotoxicity of 
different ways.[11-17]
MATERIALS AND METHODS
The experiments were performed on 50 adult Wistar rats 
weighing 220 ± 20 g. All manipulations with animals were 
performed in compliance with the “European Convention for 
the protection of vertebrate animals used for experimental or 
other scientific purposes” (Derective2010/63/EU). All the 
experiments were approved by the local ethics committee 
(Protocol No. 7-2017 October 11, 2017).
All rats were divided into five experimental groups of 10 
animals. The first group (n = 10), control, were administrated 
intraperitoneally with physiological solution. The second 
group (n = 10) were administrated intraperitoneally with 
DOX (Teva) in a cumulative dose of 20 mg/kg, once. In three 
other groups on the background of administration of DOX 
(20 mg/kg), cardioprotectors which are most frequently used 
in cancer patients were administered: Enalaprilat (KRKA 
Slovenia) 5 mg/kg intraperitoneally every 12 h; verapamil 
(JSC Alkaloid, Macedonia) 5 mg/kg intraperitoneally once 
a day; and carvedilol (Teva, Israel) per os once a day. After 
48 h, the hearts were removed from animals under Zoletil 
anesthesia (30 mg/kg). After the arrest of autonomic heart 
contractions, we isolated aorta and separated connective 
tissue. Then, the aorta was cannulated and we performed a 
retrograde perfusion of the heart by the Langendorff method 
with the Krebs-Henseleit solution. The contractile function of 
the heart was recorded with the help of a latex balloon inserted 
into the left ventricle cavity, connected to a pressure sensor, 
built into the apparatus for physiological studies of MP150 
of BiopacSystems, Inc. (California, USA) and the original 
application program of the company “BiopacSystems, Inc.” 
(California, USA). The balloon was filled with distilled 
water, the volume of which was sufficient to create end-
diastolic pressure in the left ventricle at the level of 3–5 
mmHg. Using the original software program AcqKnowledge 
of the “BiopacSystems, Inc.” company (California, USA), all 
rats were performed the check of the contractility indices: 
Left ventricular pressure (LVP, mmHg), heart rate (HR, 
bpm), maximum contraction rate (+dp/dtmax, mmHg/s), and 
maximum relaxation rate (-dp/dtmax, mmHg/s). To a high HR 
stimulation (480 bmp), the metallic cannula was attached 
to a ground connector of an electrical stimulator and a left 
atrial was attached to a positive connector. After 20 min of 
perfusion, the heart was subjected to electrical stimulation 
pulses using the STM 200-1 device of the “BiopacSystems, 
Inc.” company (California, USA) for 15 s.
To assess the myocardium functional capacity, we used a 
diastolic dysfunction coefficient or “diastolic defect” (S
tТТI
) 
calculated from the dynamic curve of the intraventricular 
pressure. The area under the curve was calculated by adding of 
trapezoids areas, which is equal to the product of its height on 
the middle line. The S
tТТI
 coefficient was expressed in c.u.[10]
Biochemical markers of damage were evaluated by standard 
methods.[18]
The study of microscope slides, photography, and 
morphometry was performed using LeicaDM 4000 B 
microscope equipped with a video recording system and 
software for archiving and image analysis, Leica Application 
Suite Version 3.8.0. A measurement of the diameters of 
cardiomyocytes in the middle part on a strictly longitudinal 
sections was conducted. The use of a single set of equipment 
for preparatory and analytical stages with simultaneous 
processing of all the material provided the standardization of 
obtained morphological data.
RESULTS AND DISCUSSION
The DOX-induced cardiomyopathy was characterized by the 
decline of myocardial contractility.
Functional tests with high-rate stimulation revealed the 
development of “diastolic defect” [Figure 1], and S
tТТI
 
increased to 8.3 ± 0.3 c.u., compared to the intact animals 1.4 
± 0.1 c.u., i.e., 8-fold [Figures 1 and 2].
The ability of DOX to damage of cell membranes was assessed 
by the change in the activity of creatine phosphokinase 
(CPK-MB) and lactate dehydrogenase (LDH) in perfusate 
[Figures 3 and 4].
Figure 1: Stress test with submaximal electrical stimulation in 
Langendorff heart of rats with DOX-induced cardiomyopathy. 
Dynamic of pressure in the left ventricle (mm Hg) with 
high-rate stimulation of the heart (480 bmp) for 15 s. DOX 
(20 mg/kg) was administrated once 48 h before the experiment
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The administration of DOX contributed to increase in the 
levels of CPK-MB and LDH in 7.1 and 8 times, respectively, 
in comparison with the intact group [Figures 3 and 4].
To confirm the functional and biochemical parameters, 
reflecting the development of cardiomyopathy on the 
background of DOX, the morphological studies were 
performed.
During the experiment in the hearts of animals of the control 
group, hypertrophy of cardiomyocytes of the left ventricle 
and increase in the size of nuclei and diameter in comparison 
with intact animals were observed [Figures 5 and 6].
A symptom of cardiomyopathy is hypertrophy of arterial 
wall of the heart, the thickness of which was 26.5 ± 0.5 µ 
Table 1: The effect of enalaprilat, carvedilol, and verapamil on the StITT (c.u.), CPK-MB (IU/l), LDH (IU/l), and 
cardiomyocyte diameter (µm) on the background of the DOX-induced cardiomyopathy (20 mg/kg once in 48 
h) (M±m; n=10)
Group StITT (c.u.) CPK-MB (IU/l) LDH (IU/l) Cardiomyocyte diameter (µm)
Intact animals 1.4±0.1* 98.0±11.8* 263.0±24.9* 8.1±0.3*
DOX (20 mg/kg) control group 8.3±0.3** 740.0±13.6** 1583.0±30.6** 17.3±0.4**
Enalaprilat (5 mg/kg) 4.1±0.1* 449.1±10.1* 987.5±26.6* 12.6±0.2*
Carvedilol (30 mg/kg) 4.6±0.2* 564.3±12.7* 1027±21.3* 13.8±0.3*
Verapamil (5 mg/kg) 5.7±0.3* 603.4±9.8* 1216.8±19.4* 14.2±0.4*
**Р<0.05 in comparison with the group of intact animals, *Р<0.05 in comparison with the control group, CPK-MB: Creatine phosphokinase, 
LDH: Lactate dehydrogenase, DOX: Doxorubicin
Figure 2: Stress test with submaximal electrical stimulation in 
Langendorff heart of rats with DOX-induced cardiomyopathy. 
Dynamic of pressure in the left ventricle (mmHg) with high-
rate stimulation of the heart (480 bmp) for 15 s. The intact 
group
Figure 3: The concentration of the creatine phosphokinase 
(CPK-MB) in perfusate. *P < 0.05 in comparison with the 
control group, **P < 0.05 in comparison with the group of 
intact animals
Figure 4: The concentration of the lactate dehydrogenase 
in perfusate. *P < 0.05 in comparison with the control group, 
**P < 0.05 in comparison with the group of intact animals
Figure 5: The myocardium of rat on the background of 
doxorubicin (20 mg/kg)
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(compared to thickness of the vessel walls of the intact animals 
10.3 ± 0.8 µm). Often hypertrophied vessels underwent 
morphological changes, indicating the development of 
cardiomyopathy. During the experiment, hypertrophy of 
left ventricular cardiomyocytes and an increase in the 
size of nuclei were found in the hearts of animals of the 
control group compared with intact animals of 17.3 ± 
0.4 µm control, and 8.1 ± 0.3 µm intact group. Therefore, 
the results of morphological studies found that the DOX-
induced cardiomyopathy on the 2nd day leads to the severe 
hypertrophy of cardiomyocytes and increasing diameter of 
cardiomyocytes [Table 1].
Thus, the functional, biochemical, and morphological 
changes demonstrate the development of pathology on the 
background of DOX (20 mg/kg) for 48 h, as expressed in 
the development of the diastolic defect when the high rate 
stimulation of the Langendorff heart of rats and the increase 
in the StТТI coefficient increased the levels of the damage 
markers CPK-MB and LDH in perfusate and hypertrophy 
of cardiomyocytes. The most informative indicator was the 
S
tТТI
 coefficient, reflecting the dynamics of the area under 
the curve of the intraventricular pressure. This coefficient 
allows to estimate the degree of myocardial damage with 
the simulation it in various ways, as well as cardioprotective 
effects of various cardiovascular drugs.
In the comparative analysis of cardioprotective activity of 
drugs in doxorubicin cardiomyopathy, the studied compounds 
were located in the following sequence: Enalaprilat (5 mg/kg), 
carvedilol (30 mg/kg), verapamil (5 mg/kg).
The obtained results allow to use S
tТТI
 at the screening of 
innovative molecules.
CONCLUSION
The fundamental difference in the area under the curve of the 
buildup of the end diastolic pressure under the conditions of 
submaximal stimulation frequencies (480 bpm) for 15 s in the 
intact group and the control group on the background of DOX 
administration naturally led to the necessity of introducing 
S
tТТI
 coefficient, which is quite revealing and informative. 
The obtained results allow to use S
tТТI
 at the screening of 
innovative molecules.
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